Mga Batayang Estadistika
| CIK | 1575659 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rapid Therapeutic Science Laboratories, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2024 |
RTSL / Rapid Therapeutic Science Laboratories, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 16, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Exact name of registrant as specified in its charter) (Exact name o |
|
| December 6, 2023 |
December 5, 2023 United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Commissioners We hereby resign as principal auditor for Rapid Therapeutic Science Laboratories, Inc, (The Company) effective November 28, 2023. |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 28, 2023 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 ( |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-41447 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 22, 2023 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 (Co |
|
| August 23, 2023 |
FORM OF COMMON STOCK PURCHASE WARRANT RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| August 23, 2023 |
FORM OF SECOND AMENDMENT, WAIVER AND PURCHASE AGREEMENT FORM OF SECOND AMENDMENT, WAIVER AND PURCHASE AGREEMENT This Second Amendment, Waiver and Purchase Agreement (this “Agreement”) is made and entered into as of August 22, 2023 (the “Effective Date”) by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 or ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-55018 Rapid Therapeutic Science Labor |
|
| July 14, 2023 |
Letter to the Company from CPA July 12, 2023 Mr. Donal Schmidt Chief Executive Officer Rapid therapeutic Science 558 County Road 472 De Leon, Texas 76444 Dear Mr. Schmidt, We hereby resign as principal auditor for Rapid Therapeutic Science Laboratories, Inc, (The Company) effective the date of this letter of notice. This is also to confirm that the client-auditor relationship between Rapid Therape |
|
| July 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event reported): July 12, 2023 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 (Commission File Nu |
|
| May 17, 2023 |
RW RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. 558 County Road 472 De Leon, Texas 76444 May 16, 2023 VIA Edgar Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re:Rapid Therapeutic Science Laboratories, Inc. Form S-1 Registration Statement File No. 333-255022 Ladies and Gentlemen: Rapid Therapeutic Science La |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2023 or ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-55018 Rapid Therapeutic Science Labo |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55018 Rapid Therapeutic Science Laboratories, Inc. (Exact name of regis |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2022 or ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-55018 Rapid Therapeutic Science |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2022 or ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-55018 Rapid Therapeutic Science Labor |
|
| July 22, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Rapid Therapeutic Science Laboratories, Inc. |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. |
|
| July 22, 2022 |
Common Stock Purchase Warrant dated April 1, 2022 to Jeffrey J. Kimbell & Associates, Inc THIS WARRANT AND ANY SHARES ISSUED BY EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE U. |
|
| May 31, 2022 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 31, 2022 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 (Commi |
|
| May 31, 2022 |
FORM OF AMENDMENT, WAIVER AND PURCHASE AGREEMENT This Amendment, Waiver and Purchase Agreement (this ?Agreement?) is made and entered into as of May 31, 2022 (the ?Effective Date?) by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| May 31, 2022 |
EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2022 or ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-55018 Rapid Therapeutic Science Labo |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 29, 2022 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 (Com |
|
| March 31, 2022 |
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split Exhibit 99.1 Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split DALLAS, TX, March 31, 2022 - Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) (?Rapid Therapeutic'' or the ?Company?), a growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announces today it has effected a 1-for-25 reverse split of its common |
|
| March 31, 2022 |
EXHIBIT A ARTICLE III AUTHORIZED CAPITAL STOCK 3.1 The Corporation shall have the authority to issue 800,000,000 shares of common stock having a par value of $0.001 per share (the ?Common Stock?). Reverse Stock Split of Outstanding Common Stock Effective as of the effective date set forth under ?Effective date and time of filing? on this Certificate of Amendment to Articles of Incorporation (or in |
|
| March 31, 2022 |
Certificate of Correction filed with the Secretary of State of Nevada on March 29, 2022 |
|
| March 16, 2022 |
Description of Securities of the Registrant Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common stock of Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (?Rapid? or the ?Company?), which common stock is registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). Only the Comp |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55018 Rapid Therapeutic Science Laboratories, Inc. (Exact name of regis |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 28, 2022 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 (C |
|
| February 1, 2022 |
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| February 1, 2022 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of January 28, 2022, by and between RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 18, 2022 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 (C |
|
| January 21, 2022 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of January 18, 2022, by and between RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. |
|
| January 21, 2022 |
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| January 18, 2022 |
First Amended and Restated Rapid Therapeutic Science Laboratories, Inc. 2020 Equity Incentive Plan FIRST AMENDED AND RESTATED RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. 2020 EQUITY INCENTIVE PLAN TABLE OF CONTENTS ARTICLE I. PREAMBLE 1 ARTICLE II. DEFINITIONS 1 ARTICLE III. ADMINISTRATION 7 ARTICLE IV. INCENTIVE STOCK OPTIONS 12 ARTICLE V. NONQUALIFIED STOCK OPTIONS 13 ARTICLE VI. INCIDENTS OF STOCK OPTIONS 14 ARTICLE VII. RESTRICTED STOCK 16 ARTICLE VIII. STOCK AWARDS 18 ARTICLE IX. PERFORMA |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 11, 2022 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 (C |
|
| January 14, 2022 |
DEF 14C 1 rtsldef14c.htm DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14c-5(d) (2)) ☒ Definitive Information |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission only (as permitted by Rule 14c-5(d) (2)) ? Definitive Information Statement ? Definitive Additional Material RAPID THERAPEU |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission only (as permitted by Rule 14c-5(d) (2)) ? Definitive Information Statement RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (N |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2021 or ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-55018 Rapid Therapeutic Science |
|
| November 10, 2021 |
Wells Asset Management NORTH TEXAS COMMERCIAL ASSOCIATION OF REALTORS? COMMERCIAL LEASE AGREEMENT between Triple D Rosegate, LLC (Landlord) and Rapid Therapeutic Scientific Laboratories, Inc. |
|
| October 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 6, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-55018 (Co |
|
| October 12, 2021 | ||
| October 12, 2021 |
Rapid Therapeutic Science Laboratories to Present at the LD Micro Main Event Conference Rapid Therapeutic Science Laboratories to Present at the LD Micro Main Event Conference DALLAS, Oct. |
|
| September 27, 2021 |
As filed with the Securities and Exchange Commission on September 27, 2021. As filed with the Securities and Exchange Commission on September 27, 2021. Registration No. 333-255022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Exact name of registrant as specified in its charter) Nevada 2834 46-2111820 (State or other |
|
| August 25, 2021 |
8-K 1 rtsl8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 25, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2021 or ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-55018 Rapid Therapeutic Science Labor |
|
| August 5, 2021 |
EX-10.3 6 rtslex103.htm FORM OF LEAK-OUT AGREEMENT LEAK-OUT AGREEMENT August 1, 2021 This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with an understanding by and among Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”). Reference is hereby ma |
|
| August 5, 2021 |
8-K 1 rtsl8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 1, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction |
|
| August 5, 2021 |
Form of Original Issue Discount Convertible Debenture Due May 1, 2022 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| August 5, 2021 |
PLACEMENT AGENT?S WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| August 5, 2021 |
EX-10.1 4 rtslex101.htm FORM OF SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2021, between Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collecti |
|
| August 5, 2021 |
EX-4.1 2 rtslex41.htm FORM OF COMMON STOCK PURCHASE WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED |
|
| July 26, 2021 |
SC 13G 1 doway13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 753431105 (CUSIP Number) February 17, 2021 (Date of Event Which Requires Filing of thi |
|
| June 2, 2021 |
8-K 1 rtsl8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 22, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction |
|
| June 2, 2021 |
INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (the ?Agreement?) is made and entered into as of the 22th day of April 2021 (the ?Effective Date?), by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| June 2, 2021 |
INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (the ?Agreement?) is made and entered into as of the 18th day of May, 2021 (the ?Effective Date?), by and between Rapid Therapeutic Science Laboratory, Inc. |
|
| June 2, 2021 |
EX-3.2 3 rtslex32.htm CERTIFICATE OF DESIGNATION SERIES C RAPID THERAPEUTIC SCIENCE LABORATORIES, INC., ESTABLISHING THE DESIGNATION, PREFERENCES, LIMITATIONS AND RELATIVE RIGHTS OF ITS SERIES C CONVERTIBLE PREFERRED STOCK Pursuant to Section 78.1955 of the Nevada Revised Statutes (the “NRS”), Rapid Therapeutic Science Laboratories, Inc., a company organized and existing under the State of Nevada |
|
| June 2, 2021 |
Rapid Therapeutic Prepares to file Investigational New Drug Application for its CBD Metered Dose Inhaler with FDA DALLAS, June 2, 2021 (GLOBE NEWSWIRE) - Rapid Therapeutic Science Laboratories, Inc. |
|
| June 2, 2021 |
the 23, LLC and Rapid Therapeutic Science Laboratories, Inc. TRADING AGREEMENT THIS TRADING AGREEMENT (this ?Agreement?), made as of this 22nd day of April 2021 (the ?Effective Date?), by and among We the 23, LLC, at Texas limited liability company and its managing member, Charles L. |
|
| June 2, 2021 |
EX-3.1 2 rtslex31.htm CERTIFICATE OF DESIGNATION SERIES B RAPID THERAPEUTIC SCIENCE LABORATORIES, INC., ESTABLISHING THE DESIGNATION, PREFERENCES, LIMITATIONS AND RELATIVE RIGHTS OF ITS SERIES B CONVERTIBLE PREFERRED STOCK Pursuant to Section 78.1955 of the Nevada Revised Statutes (the “NRS”), Rapid Therapeutic Science Laboratories, Inc., a company organized and existing under the State of Nevada |
|
| May 14, 2021 |
Form of Subscription Agreement $0.40 Per Share (First and Second Quarter 2021 Private Offering) EX-10.7 2 rtslex107.htm SUBSCRIPTION AGREEMENT THE SECURITIES TO BE ISSUED PURSUANT TO THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), OR ANY OTHER APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED THEREUNDER OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. SUBSCRIPTION AGREEMENT $0.40 PER SHARE Nam |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2021 or ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-55018 Rapid Therapeutic Science Labo |
|
| April 14, 2021 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 rtsl8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 13, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction |
|
| April 5, 2021 |
Registration Statement - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on April 2, 2021. Registration No. 333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Exact name of registrant as specified in its charter) Nevada 2834 46-2111820 (State or other jurisdiction of incorporation or |
|
| March 16, 2021 |
Description of Securities of the Registrant EX-4.1 2 rtslex41.htm DESCRIPTION OF SECURITIES OF THE REGISTRANT Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common stock of Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (“Rapid” or the “Company”), which common stock is registered pursuant to Section 12 of the Securities Ex |
|
| March 16, 2021 |
- RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. - FORM 10-KT SEC FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-KT ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from April 1, 2020 to December 31, 2020 Commission File Number: 000-55018 Rapid Therapeutic Science Laborator |
|
| March 16, 2021 |
Subsidiaries of the Registrant EX-21.1 3 rtslex211.htm SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 Subsidiaries Power Blockchain, LLC (Wyoming limited liability company) - Wholly-owned Rxoid Health Solutions, LLC (Texas limited liability company) - Wholly-owned |
|
| February 16, 2021 |
SETTLEMENT AND MUTUAL RELEASE AGREEMENT SETTLEMENT AND MUTUAL RELEASE AGREEMENT This Settlement and Mutual Release Agreement (this ?Agreement?) dated February 2, 2021, is by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 3, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorpo |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 10, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organizat |
|
| February 16, 2021 |
EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (the ?Agreement?) is made and entered into as of the 9th day of February 2021 (the ?Effective Date?), by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| February 9, 2021 |
RAPID THERAPEUTICS SCIENCE LABORATORIES, INC. WHISTLEBLOWER PROTECTION POLICY RAPID THERAPEUTICS SCIENCE LABORATORIES, INC. WHISTLEBLOWER PROTECTION POLICY I.INTRODUCTION Rapid Therapeutics Science Laboratories, Inc. (the “Company”) is committed to providing a workplace that is conducive to open discussion of its business practices. It is Company policy to comply with all applicable laws, including laws that protect employees against unlawful discrimination or retaliation b |
|
| February 9, 2021 |
Rapid Therapeutics Science Laboratories, Inc. (the “Company”) Nominating and Corporate Governance Committee Charter Role: The Nominating and Corporate Governance Committee’s role is to determine the slate of director nominees for election to the Company’s Board of Directors (the “Board”) to identify and recommend candidates to fill vacancies occurring between annual stockholder meetings, to review |
|
| February 9, 2021 |
Rapid Therapeutics Science Laboratories, Inc. (the “Company”) Compensation Committee Charter EX-99.2 8 rtslex992.htm CHARTER OF THE COMPENSATION COMMITTEE Rapid Therapeutics Science Laboratories, Inc. (the “Company”) Compensation Committee Charter Role: The Compensation Committee’s role is to discharge the Board of Directors (the “Board’s”) responsibilities relating to compensation of the Company’s executives and to oversee and advise the Board on the adoption of policies that govern the |
|
| February 9, 2021 |
Rapid Therapeutics Science Laboratories, Inc. (the “Company”) Audit Committee Charter EX-99.1 7 rtslex991.htm CHARTER OF THE AUDIT COMMITTEE Rapid Therapeutics Science Laboratories, Inc. (the “Company”) Audit Committee Charter Role: The Audit Committee of the Board assists the Board in fulfilling its responsibility for oversight of and integrity of the accounting, auditing, and reporting practices of the Company, and such other duties as directed by the Board. The Committee’s purpo |
|
| February 9, 2021 |
EX-2.1 2 rtslex21.htm MEMBERSHIP INTEREST PURCHASE AGREEMENT DATED NOVEMBER 30, 2020 MEMBERSHIP INTEREST PURCHASE AGREEMENT BY AND BETWEEN THE SOLE MEMBER OF RXOID HEALTH SOLUTIONS, LLC, A TEXAS LIMITED LIABILITY COMPANY AND RAPID THERAPEUTIC SCIENCE LABORATORIES, INC., A NEVADA CORPORATION DATED NOVEMBER 30, 2020 TABLE OF CONTENTS ARTICLE 1 PURCHASE AND SALE 1 1.1 Agreement to Purchase and Sell 1 |
|
| February 9, 2021 |
SETTLEMENT AND MUTUAL RELEASE AGREEMENT This Settlement and Mutual Release Agreement (this “Agreement”) dated February 9, 2021, is by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| February 9, 2021 |
8-K 1 rtsl8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 3, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdictio |
|
| February 9, 2021 |
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. 2020 EQUITY INCENTIVE PLAN TABLE OF CONTENTS ARTICLE I. PREAMBLE 1 ARTICLE II. DEFINITIONS 1 ARTICLE III. ADMINISTRATION 6 ARTICLE IV. INCENTIVE STOCK OPTIONS 10 ARTICLE V. NONQUALIFIED STOCK OPTIONS 11 ARTICLE VI. INCIDENTS OF STOCK OPTIONS 12 ARTICLE VII. RESTRICTED STOCK 14 ARTICLE VIII. STOCK AWARDS 15 ARTICLE IX. PERFORMANCE SHARES 16 ARTICLE X. CH |
|
| February 9, 2021 |
EX-10.2 4 rtslex102.htm EXCLUSIVE LICENSE AGREEMENT DATED FEBRUARY 9, 2021 EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 9th day of February 2021 (the “Effective Date”), by and between Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Manufacturer”), EM3 Methodologies, LLC, an Arizona limited liability compa |
|
| February 9, 2021 |
EX-14.1 6 rtslex141.htm CODE OF ETHICS CODE OF ETHICAL BUSINESS CONDUCT Rapid Therapeutics Science Laboratories, Inc. (the “Company”) has enjoyed a reputation as a company of high integrity. The Company has worked hard to earn the respect of customers, suppliers, and the public. This Code of Ethical Business Conduct (“Code”) embodies the Company’s commitment to continue to enjoy this fine reputati |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 753431105 (CUSIP Number) Donal R. Schmidt, Jr. 5580 Peterson Lane, Suite 200 Dallas, Texas 75240 (800) 497-6059 (Name, Ad |
|
| February 4, 2021 |
SC 13D 1 sean13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 753431105 (CUSIP Number) Sean Berrier 7108 Duffield Dr. Dallas, Texas 75248 (214) 502-6 |
|
| February 4, 2021 |
EX-99.1 2 donsex991.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated February 3, 2021 (including amendments thereto) with respect to the Common Stock of Rapid Therapeutics Labor |
|
| January 26, 2021 |
Trading Agreement dated January 11, 2021, with Duane Drinkwine EX-10.4 5 rtslex104.htm TRADING AGREEMENT DATED JANUARY 11, 2021, WITH DUANE DRINKWINE TRADING AGREEMENT THIS TRADING AGREEMENT (this “Agreement”), made as of this 7th day of January 2021 (the “Effective Date”), by and among the individuals or entities who have signed a form of page 8 of this Agreement below (each a “Signature Page”, each signatory a “Shareholder” and collectively if more than one |
|
| January 26, 2021 |
8-K 1 rtsl8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 11, 2021 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdictio |
|
| January 26, 2021 |
Form of Common Stock Purchase Warrant (January 2021 Private Offering) EX-10.2 3 rtslex102.htm FORM OF COMMON STOCK PURCHASE WARRANT (JANUARY 2021 PRIVATE OFFERING) NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AN |
|
| January 26, 2021 |
Employment Agreement with Duane Drinkwine dated January 11, 2021 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| January 26, 2021 |
Form of Subscription Agreement $0.40 Per Share (January 2021 Private Offering) EX-10.1 2 rtslex101.htm FORM OF SUBSCRIPTION AGREEMENT $0.40 PER SHARE (JANUARY 2021 PRIVATE OFFERING) THE SECURITIES TO BE ISSUED PURSUANT TO THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), OR ANY OTHER APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED THEREUNDER OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION |
|
| January 25, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 753431105 (CUSIP Number) December 2, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 8, 2021 |
Financial Statements and Exhibits 8-K/A 1 rtsl8ka.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 12, 2020 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (S |
|
| January 8, 2021 |
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. PRO FORMA BALANCE SHEET SEPTEMBER 30, 2020 Pro Forma As Reported Adjustments As Adjusted Assets Current assets: Cash and cash equivalents $ 266,055 $ - $ 266,055 Inventory 192,746 - 192,746 Total current assets 458,801 - 458,801 Property and equipment: Property and equipment 92,979 500,000 (A) 592,979 92,979 500,000 592,979 Less: Accumulated depreciatio |
|
| January 8, 2021 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-99.1 2 rtslex991.htm AUDITED FINANCIAL STATEMENTS REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Rapid Therapeutic Science Laboratories, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of Razor Jacket, LLC (the “Company), as of September 30, 2020 and March 31, 2020, and the related statements of oper |
|
| December 31, 2020 |
- DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission only (as permitted by Rule 14c-5(d) (2)) [X] Definitive Information Statement RAPID THERAPEUTIC SCIENCE LABORATORIES, I |
|
| December 31, 2020 |
- DEFINITIVE ADDITIONAL MATERIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission only (as permitted by Rule 14c-5(d) (2)) [ ] Definitive Information Statement [X] Definitive Additional Material Rapid |
|
| December 18, 2020 |
Other Events, Shareholder Director Nominations - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 18, 2020 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organizat |
|
| December 18, 2020 |
- PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission only (as permitted by Rule 14c-5(d) (2)) [ ] Definitive Information Statement RAPID THERAPEUTIC SCIENCE LABORATORIES, I |
|
| December 7, 2020 |
8-K 1 rtsl8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 2, 2020 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdictio |
|
| December 7, 2020 |
TRADING AGREEMENT THIS TRADING AGREEMENT (this “Agreement”), made as of this day of (the “Effective Date”), by and among the individuals and entities who have signed a form of page 6 of this Agreement below (each a “Signature Page”, each signatory a “Shareholder” and collectively, the “Shareholders”) and Rapid Therapeutic Science Laboratories, Inc. |
|
| December 7, 2020 |
SUBSCRIPTION AGREEMENT $0.40 PER SHARE THE SECURITIES TO BE ISSUED PURSUANT TO THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), OR ANY OTHER APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED THEREUNDER OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. |
|
| November 18, 2020 |
EX-10.3 6 rtslex103.htm ASSIGNMENT OF INTELLECTUAL PROPERTY AGREEMENT DATED NOVEMBER 16, 2020 ASSIGNMENT OF INTELLECTUAL PROPERTY THIS ASSIGNMENT OF INTELLECTUAL PROPERTY (this “Assignment”) is entered into effective as November 16, 2020 (the “Effective Date”), by and between Frank Gill, Ryan Johnson and Razor Jacket, LLC, respectively individuals living in Oregon and an Oregon limited liability c |
|
| November 18, 2020 |
EX-2.2 2 rtslex22.htm FIRST AMENDMENT TO ASSET PURCHASE AND SALES AGREEMENT DATED NOVEMBER 16, 2020 FIRST AMENDMENT TO PURCHASE AGREEMENT This First Amendment to Purchase Agreement (this “Agreement”), dated and effective November 16, 2020 (the “Effective Date”), amends that certain Asset Purchase sand Sales Agreement, dated October 23, 20201 (the “Purchase Agreement”), entered into by and between |
|
| November 18, 2020 |
EX-10.5 8 rtslex105.htm TRADING AGREEMENT DATED NOVEMBER 16, 2020, BETWEEN FRANK GILL, RYAN JOHNSON AND RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. TRADING AGREEMENT THIS TRADING AGREEMENT (this “Agreement”), made as of this 16th day of November 2020 (the “Effective Date”), by and among the individuals or entities who have signed a form of page 8 of this Agreement below (each a “Signature Page”, |
|
| November 18, 2020 |
EX-10.4 7 rtslex104.htm TRADING AGREEMENT DATED NOVEMBER 16, 2020, BETWEEN FRANK GILL AND RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. TRADING AGREEMENT THIS TRADING AGREEMENT (this “Agreement”), made as of this 16th day of November 2020 (the “Effective Date”), by and among the individuals or entities who have signed a form of page 8 of this Agreement below (each a “Signature Page”, each signatory |
|
| November 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 12, 2020 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organizat |
|
| November 18, 2020 |
EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| November 18, 2020 |
EX-3.1 3 rtslex31.htm CERTIFICATE OF DESIGNATION FILED WITH THE SECRETARY OF STATE OF NEVADA ON NOVEMBER 12, 2020 Certificate, Amendment or Withdrawal of Designation NRS.1955, 78.1955(6) [X] Certificate of Designation 1. Entity information: Name of entity: RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. Entity or Nevada Business Identification Number (NVID): E00093122013-4 2. Effective date and For C |
|
| November 18, 2020 |
EX-10.1 4 rtslex101.htm EMPLOYMENT AGREEMENT ENTERED INTO BETWEEN RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. AND FRANK GILL, DATED NOVEMBER 16, 2020 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into by and between Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), and Frank Gill, an individual (“Employee”) and shall be eff |
|
| November 9, 2020 |
Quarterly Report - QUARTERLY REPORT 10-Q 1 rtsl10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2020 Commission File No. 000-55018 [ ] Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition peri |
|
| October 29, 2020 |
ASSET PURCHASE AND SALES AGREEMENT This Asset Purchase and Sales Agreement (this “Agreement”) is made and entered into as of the 23rd day of October 2020, by and between Rapid Therapeutic Science Laboratories, Inc. |
|
| October 29, 2020 |
8-K 1 rtsl8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 23, 2020 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdictio |
|
| October 21, 2020 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 31, 2020 RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organizatio |
|
| August 27, 2020 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 EX-4.1 2 rtslex41.htm DESCRIPTION OF SECURITIES OF THE REGISTRANT Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common stock of Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (“Rapid Therapeutic” or the “Company”), which is registered pursuant to Section 12 of the Securities Exc |
|
| August 27, 2020 |
Exhibit 10.4 EXCLUSIVE LICENSE and SALES AND LICENSING AGREEMENTS FIRST AMENDMENT THIS FIRST AMENDEMENT (the “First Amendment”) is made and entered into as of the 25th day of June 2020 (the “Effective Date”). by and between Rapid Therapeutic Science Laboratories, Inc., a Nevada for profit company, on behalf of its assignor, Texas MDI, Inc. a Texas for-profit corporation (the “Manufacturer”) and EM |
|
| August 27, 2020 |
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. 2018 AMENDED AND RESTATED STOCK PLAN EX-10.1 3 rtslex101.htm RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. 2018 STOCK PLAN Exhibit 10.1 RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. 2018 AMENDED AND RESTATED STOCK PLAN The board of directors of Directors of the Company has unanimously approved the 2018 Stock Plan (the “Plan”). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awa |
|
| August 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 Rapid Th |
|
| August 27, 2020 |
EX-21.1 5 rtslex211.htm SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES Power Blockchain, LLC (a Wyoming limited liability company, wholly-owned) |
|
| August 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2020 Commission File No. 000-55018 [ ] Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to RAPID THERAPEUTIC SCIENCE LABO |
|
| August 13, 2020 |
Form of Subscription Agreement (August 2020) THE SECURITIES TO BE ISSUED PURSUANT TO THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), OR ANY OTHER APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED THEREUNDER OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. |
|
| July 6, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event reported): June 30, 2020 RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 000-55018 (Co |
|
| July 6, 2020 |
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June, 30, 2020, by and between RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. |
|
| June 29, 2020 |
10-K 1 rtsl10k.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 Commission File Number: 000-55018 Rapid Therapeutic Science Laboratories, Inc. (Exact name of registrant as specified in its charter) Nevada 46-2111820 (S |
|
| March 31, 2020 |
MINR / Holly Brothers Pictures, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT 10-Q 1 rtsl10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended December 31, 2019 Commission File No. 000-55018 RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Exact Name of Registrant as specified in its charter) Nevada 46-2111820 (St |
|
| March 27, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 rtsl8k.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event reported): March 27, 2020 RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporati |
|
| March 27, 2020 |
Prager Metis CPA’s, LLC 222 MOUNT AIRY ROAD BASKING RIDGE, NJ 07920 T 908.766.9800 F 908.766.9811 www.pragermetis.com March 27, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 We have read the statements made by Rapid Therapeutic Science Laboratories, Inc. under Item 4.01 of its Form 8-K dated March 27, 2020. We agree with the statements concerning our Firm in such |
|
| February 20, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event reported): February 19, 2020 RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 000-55018 |
|
| February 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-37758 CUSIP NUMBER 753431105 NOTIFICATION OF LATE FILING (Check one): [] Form 10-K [] Form 10-D [] Form 20-F [] Form N-SAR [] Form 11-K [] Form N-CSR [X] Form 10-Q For Period Ended: December 31, 2019 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form |
|
| January 21, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event reported): January 14, 2020 HOLLY BROTHERS PICTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 000-55018 (Commission Fil |
|
| January 21, 2020 |
Amended and Restated Articles of Incorporation Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390) Certificate to Accompany Restated Articles or Amended and Restated Articles (PURSUANT TO NRS 78.403) Officer's Statement (PURSUANT TO NRS 80.030) 1. Entity information: Name of entity as on file with the Nevada Secretary of State: Holly Brothers Pictures, Inc. Entity or Nevada Business Identification Number (NVID |
|
| December 13, 2019 |
MINR / Holly Brothers Pictures, Inc. DEF 14C - - DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ]Preliminary Information Statement [ ]Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) [X]Definitive Information Statement HOLLY BROTHERS PICTURES, INC. (Na |
|
| December 3, 2019 |
MINR / Holly Brothers Pictures, Inc. PRE 14C - - PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X]Preliminary Information Statement [ ]Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) [ ]Definitive Information Statement HOLLY BROTHERS PICTURES, INC. (Na |
|
| November 22, 2019 |
EX-10.2 3 minrex102.htm FORM OF PROMISSORY NOTE ISSUED BY HOLLY BROTHERS PICTURES, INC. TO AN INVESTOR, DATED AS OF NOVEMBER 18, 2019, WITH A FIVE YEAR MATURITY THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIP |
|
| November 22, 2019 |
This SUBLICENSE AGREEMENT (the “Agreement”) effective as of November 15, 2019 (the “Effective Date”) is entered into by and between Texas MDI, Lnc. |
|
| November 22, 2019 |
8-K 1 minr8k.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event reported): November 15, 2019 HOLLY BROTHERS PICTURES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organi |
|
| November 22, 2019 |
EX-10.3 4 minrex103.htm FORM OF PROMISSORY NOTE ISSUED BY HOLLY BROTHERS PICTURES, INC. TO AN INVESTOR, DATED AS OF NOVEMBER 18, 2019, WITH VARIABLE MATURITY TERMS THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) REC |
|
| November 22, 2019 |
EX-10.4 5 minrex104.htm FORM OF AMENDMENT TO CERTAIN PROMISSORY NOTES ISSUED BY HOLLY BROTHERS PICTURES, INC. TO VARIOUS HOLDERS, DATED AS OF NOVEMBER 18, 2019 AMENDMENT TO PROMISSORY NOTES This amendment (“Amendment”), dated as of November 18, 2019, is to those certain Promissory Notes in the total principal amount of $737,835.00 (the “Notes”), by and among Holly Brothers Pictures, Inc., a Nevada |
|
| November 5, 2019 |
MINR / Holly Brothers Pictures, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2019 Commission File No. 000-55018 HOLLY BROTHERS PICTURES, INC. (Exact Name of Registrant as specified in its charter) Nevada 46-2111820 (State or other jurisdiction of incorporation) (IRS E |
|
| July 26, 2019 |
MINR / Holly Brothers Pictures, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2019 Commission File No. 000-55018 Holly Brothers Pictures, Inc. (Exact name of registrant as specified in its charter) Nevada 46-2111820 (State or other jurisdiction of (I.R.S. Employer incorpor |
|
| July 9, 2019 |
MINR / Holly Brothers Pictures, Inc. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 Commission File Number: 000-55018 Holly Brothers Pictures, Inc. (Exact name of registrant as specified in its charter) Nevada 46-2111820 (State or Other Jurisdiction of (I.R.S. Employer I |
|
| July 1, 2019 |
MINR / Holly Brothers Pictures, Inc. NT 10-K - - FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-37758 CUSIP NUMBER 435736103 NOTIFICATION OF LATE FILING (Check one): [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: March 31, 2019 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11 |
|
| April 24, 2019 |
April 24, 2019 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| April 24, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 minr8k.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT: April 24, 2019 HOLLY BROTHERS PICTURES, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55018 46-2111820 (State or Other Jurisdiction of Incorporation or Organization) (Commiss |
|
| February 14, 2019 |
MINR / Holly Brothers Pictures, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended December 31, 2018 Commission File No. 000-55018 HOLLY BROTHERS PICTURES, INC. (Exact Name of Registrant as specified in its charter) Nevada 46-2111820 (State or other jurisdiction of incorporation) (IRS Em |
|
| January 15, 2019 |
MINR / Holly Brothers Pictures, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2018 Commission File No. 000-55018 HOLLY BROTHERS PICTURES, INC. (Exact Name of Registrant as specified in its charter) Nevada 46-2111820 (State or other jurisdiction of incorporation) (IRS E |
|
| January 15, 2019 |
MINR / Holly Brothers Pictures, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2018 Commission File No. 000-55018 HOLLY BROTHERS PICTURES, INC. (Exact Name of Registrant as specified in its charter) Nevada 46-2111820 (State or other jurisdiction of incorporation) (IRS Employ |
|
| December 6, 2018 |
MINR / Holly Brothers Pictures, Inc. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 Commission File Number: 000-55018 Holly Brothers Pictures, Inc. (Exact name of registrant as specified in its charter) Nevada 46-2111820 (State or Other Jurisdiction of Incorporation or O |
|
| November 13, 2018 |
MINR / Holly Brothers Pictures, Inc. FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-37758 CUSIP NUMBER 435736103 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: September 30, 2018 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Fo |
|
| August 15, 2018 |
MINR / Holly Brothers Pictures, Inc. FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-37758 CUSIP NUMBER 60855D 101 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [] Form 20-F [] Form 11-K [X] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: June 30, 2018 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 1 |
|
| June 29, 2018 |
MINR / Holly Brothers Pictures, Inc. FORM 12B-25 NT 10-K 1 hllynt10k.htm FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-37758 CUSIP NUMBER 60855D 101 NOTIFICATION OF LATE FILING (Check one): [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: March 31, 2018 [] Transition Report on Form 10-K [] Transition Report on Form |
|
| March 29, 2018 |
SETTLEMENT AND MUTUAL RELEASE AGREEMENT SETTLEMENT AND MUTUAL RELEASE AGREEMENT This Settlement and Mutual Release Agreement (the “Agreement”) is made effective as of March 21, 2018, by and between Pioneer Group, LLC (“Pioneer”), Black Car, Inc. |
|
| March 29, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2018 HOLLY BROTHERS PICTURES, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55018 46-2111820 (State or Other Jurisdiction of Incorporation or Organi |
|
| March 29, 2018 |
EX-10.2 3 hllyex102.htm STIPULATION AND PROPOSED ORDER THEREON, DATED MARCH 22, 2018 John E. Dolkart, Jr., SBN 259707 LAW OFFICES OF JOHN E. DOLKART, JR. 1750 Kettner Blvd., Suite 416 San Diego, California 92101 Tel: (619) 501-1083 Fax: (619) 684-3512 [email protected] Attorney for: Plaintiffs SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SAN DIEGO – CENTRAL DIVISION PIONEER GROUP, LLC, a |
|
| March 29, 2018 |
begin 644 hllyex102.pdf M)5!$1BTQ+C4-)>+CS],-"C$X(# @;V)J#3P\+TQI;F5A , +I0)F0T*96YD%LP(# @-C$R(#UK8)<&]AD"QAB!5+0'@4Y1=J>, M[&DZA'?OV*S(BS+9I$M#+Y6B;!P^3Z?L]+%^G]1I38'W"5)^'Y@7Z]KZYDA% M6!=;+ 15X,V LGM346)O1I33;[\JBV5BZFMV=3)G"-8WTRGU^QL-CM.*W,+ M0M*Z&YO@\@I^I'EEK'$.R)*CYC4Y!W[(!5O\VIBN2E9L?'PZM7N/JJ59UZ"$ M8K-T\\%D=>U[91@LNTM-D/6$5W?L-.C%\YP4"P>9[>5;9% G7LKGE\7#Q> M3Q E3$3(00Y4:"\)^QM M?5]=*\YO^ |
|
| March 9, 2018 |
CONSULTING AGREEMENT This CONSULTING AGREEMENT is made effective as of the date set forth below by and between Canmore International, Inc. |
|
| March 9, 2018 |
AMENDMENT TO EMPLOYMENT AGREEMENT AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (“Amendment”) is entered into effective as of February 15, 2018 and serves to amend the Employment Agreement entered into by and between Holly Brothers Pictures, Inc. |
|
| March 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2018 HOLLY BROTHERS PICTURES, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55018 46-2111820 (State or Other Jurisdiction of Incorporation or Org |
|
| March 5, 2018 |
Rapid Therapeutic Science Laboratories, Inc. 2018 Amended and Restated Stock Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement HOLLY BROTHERS PICTURES, INC. |
|
| February 22, 2018 |
MINR / Holly Brothers Pictures, Inc. / Bond Steve - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Holly Brothers Pictures, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 435736 103 (CUSIP Number) Steve Bond c/o Holly Brothers Pictures, Inc. 462 Stevens Ave, #310 Solana Beach, CA 92075 Phone: 858-987-4910 (Name, Address |
|
| February 22, 2018 |
MINR / Holly Brothers Pictures, Inc. / Willson Brent - SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Holly Brothers Pictures, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 435736 103 (CUSIP Number) Brent Willson c/o Holly Brothers Pictures, Inc. 462 Stevens Ave, #310 Solana Beach, CA 92075 Phone: 858-987-4910 (Name, Addr |
|
| February 20, 2018 |
HLLY / Holly Brothers Pictures, Inc. PRELIMINARY INFORMATION STATEMENT PRE14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement HOLLY BROTHERS PICTURES |
|
| February 2, 2018 |
PROMISSORY NOTE $__________ _________, 2018 ex-10.5 PROMISSORY NOTE $ , 2018 FOR VALUE RECEIVED, the undersigned, HOLLY BROTHERS PICTURES, INC. (herein called the ?Company?), a corporation organized and existing under the laws of the State of Nevada, with its principal place of business at 8221 E. Washington Street, Chagrin Falls, OH 44023, hereby promises to pay to the order of , (the ?Lenders?), at such place as the Lenders may from time |
|
| February 2, 2018 |
EX-10.3 4 hllyex103.htm EXCHANGE AGREEMENT BETWEEN HOLLY BROTHERS PICTURES, INC., PBC GROUP, LLC AND BLACK CAR, INC. DATED FEBRUARY 1, 2018 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (this “Agreement”) is entered into as of February 1, 2018, by and among Holly Brothers Pictures, Inc., a Nevada corporation (the “Company”), PBC Group, LLC and Black Car, Inc. (collectively, the “Members”), and Power |
|
| February 2, 2018 |
EX-10.1 2 hllyex101.htm EMPLOYMENT AGREEMENT BETWEEN HOLLY BROTHERS PICTURES, INC. AND BRENT WILLSON DATED JANUARY 29, 2018 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 29, 2018 (the “Effective Date”), by and between Holly Brothers Pictures, Inc., a Nevada corporation (the “Company”), and Brent Willson (“Executive”, and the Company and the Executiv |
|
| February 2, 2018 |
EX-10.2 3 hllyex102.htm EMPLOYMENT AGREEMENT BETWEEN HOLLY BROTHERS PICTURES, INC. AND STEVE BOND DATED JANUARY 29, 2018 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 29, 2018 (the “Effective Date”), by and between Holly Brothers Pictures, Inc., a Nevada corporation (the “Company”), and Steve Bond (“Executive”, and the Company and the Executive coll |
|
| February 2, 2018 |
EX-10.4 5 hllyex104.htm FORM OF FIVE-YEAR NOTE ISSUED IN EXCHANGE AGREEMENT BETWEEN HOLLY BROTHERS PICTURES, INC., PBC GROUP, LLC AND BLACK CAR, INC. DATED FEBRUARY 1, 2018 THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR |
|
| February 2, 2018 |
8-K 1 hlly8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JANUARY 25, 2018 HOLLY BROTHERS PICTURES, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 000-55018 46-2111820 (State or Other Juris |
|
| January 29, 2018 |
MINR / Holly Brothers Pictures, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 H |
|
| December 13, 2017 |
8-K 1 hlly8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 22, 2017 Holly Brothers Pictures, Inc. (Exact Name of Registrant as Specified in Charter) Nevada 000-55018 46-2111820 (State or Other Jurisdiction of Incorpo |
|
| November 7, 2017 |
MINR / Holly Brothers Pictures, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 |
|
| August 10, 2017 |
MINR / Holly Brothers Pictures, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 Holly |
|
| July 14, 2017 |
MINR / Holly Brothers Pictures, Inc. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year endedMarch31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 Holly Brothers |
|
| June 29, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on F |
|
| June 7, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2017 PowerMedChairs (Exact Name of Registrant as Specified in Charter) Nevada 000-55018 46-2111820 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R |
|
| June 7, 2017 |
Exhibit 3.1 |
|
| May 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement POWERMEDCHAIRS (Name of Registrant A |
|
| April 26, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement POWERMEDCHAIRS (Name of Registrant A |
|
| February 1, 2017 |
PowerMedChairs QUARTERLY REPORT (Quarterly Report) 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-550 |
|
| October 13, 2016 |
PowerMedChairs QUARTERLY REPORT (Quarterly Report) 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55 |
|
| October 11, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 adt8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2016 PowerMedChairs (Exact name of registrant as specified in its charter) Commission File Number: 000-55018 Nevada 46-2111820 (State or other jurisdiction |
|
| October 11, 2016 |
Exhibit 16.1 Seale & Beers, CPAs Certified Public Accountants PCAOB Registered Auditors ? www.sealebeers.com October 7, 2016 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Dear Sir/Madam: We have read the statements included under Item 4.01 in the Form 8-K dated October 7, 2016 of PowerMedChairs (the "Company") to be filed with the Securit |
|
| August 15, 2016 |
PowerMedChairs QUARTERLY REPORT (Quarterly Report) 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 P |
|
| August 15, 2016 |
PowerMedChairs QUARTERLY REPORT (Quarterly Report) 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 P |
|
| June 17, 2016 |
PowerMedChairs ANNUAL REPORT (Annual Report) 10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 PowerMe |
|
| February 4, 2016 |
MINR / Holly Brothers Pictures, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 P |
|
| November 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2015 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 Powe |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K X Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report |
|
| August 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2015 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 PowerMedC |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K X Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Fo |
|
| July 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 PowerMedChairs ( |
|
| June 30, 2015 |
NT 10-K 1 pmcnt10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): X Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2014 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 Power |
|
| November 3, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2014 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 Powe |
|
| August 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2014 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 PowerMedC |
|
| July 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 PowerMedChairs ( |
|
| June 30, 2014 |
MINR / Holly Brothers Pictures, Inc. NT 10-K - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): X Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2014 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on F |
|
| February 14, 2014 |
PowerMedChairs (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 PowerMe |
|
| November 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 PowerM |
|
| August 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55018 PowerMedCha |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K X Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2013 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Fo |
|
| August 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 PowerMedChairs (Exact name of registrant as specified in its charter) Nevada 333-188781 46-2111820 (State or other jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification Number) 8221 E. |
|
| August 5, 2013 |
PROSPECTUS 204,000 SHARES OF COMMON STOCK - $0.10 PER SHARE PROSPECTUS PowerMedChairs 204,000 SHARES OF COMMON STOCK - $0.10 PER SHARE The selling stockholders of PowerMedChairs (the "Company") named in this prospectus are offering shares of Common Stock through this Prospectus. The Company will not receive any of the proceeds from the sale of the shares by the selling stockholders. Our Common Stock is presently not traded on any market or securities excha |
|
| July 30, 2013 |
PowerMedChairs A Nevada Corporation 8221 E. Washington Street, Chagrin Falls, OH 44023 Telephone: (440) 543-4645 July 30, 2013 VIA EDGAR TRANSMISSION U. S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street N.E. Washington, DC 20549 Attn: Mr. Brian Soares Re: PowerMedChairs File No.: 333-188781 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to |
|
| July 26, 2013 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON JULY 25, 2013 REGISTRATION NO. 333-188781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PowerMedChairs (Exact name of registrant as specified in its charter) Nevada 3842 46-2111820 (State or Other Jurisdiction (Primary Standar |
|
| July 25, 2013 |
CORRESP 1 filename1.htm PowerMedChairs A Nevada Corporation 8221 E. Washington Street, Chagrin Falls, OH 44023 Telephone: (440) 543-4645 July 25, 2013 VIA EDGAR TRANSMISSION U. S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E., Mail Stop 3030 Washington, D.C. 20549 Attn: Mr. Brian Soares Re: PowerMedChairs Amendment No. 2 to Registration Statement on Form S-1 F |
|
| July 25, 2013 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON JULY 25, 2013 REGISTRATION NO. 333-188781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PowerMedChairs (Exact name of registrant as specified in its charter) Nevada 3842 46-2111820 (State or Other Jurisdiction (Primary Standar |
|
| July 16, 2013 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON JULY 16, 2013 REGISTRATION NO. 333-188781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PowerMedChairs (Exact name of registrant as specified in its charter) Nevada 3842 46-2111820 (State or Other Jurisdiction (Primary Standar |
|
| July 16, 2013 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON JULY 12, 2013 REGISTRATION NO. 333-188781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PowerMedChairs (Exact name of registrant as specified in its charter) Nevada 3842 46-2111820 (State or Other Jurisdiction (Primary Standar |
|
| July 16, 2013 |
CORRESP 1 filename1.htm PowerMedChairs A Nevada Corporation 8221 E. Washington Street, Chagrin Falls, OH 44023 Telephone: (440) 543-4645 July 16, 2013 VIA EDGAR TRANSMISSION U. S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E., Mail Stop 3030 Washington, D.C. 20549 Attn: Mr. Brian Soares Re: PowerMedChairs Amendment No. 1 to Registration Statement on Form S-1 F |
|
| June 25, 2013 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON JUNE 25, 2013 REGISTRATION NO. 333-188781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PowerMedChairs (Exact name of registrant as specified in its charter) Nevada 3842 46-2111820 (State or Other Jurisdiction (Primary Standard |
|
| June 25, 2013 |
CORRESP 1 filename1.htm PowerMedChairs A Nevada Corporation 8221 E. Washington Street, Chagrin Falls, OH 44023 Telephone: (440) 543-4645 June 24, 2013 VIA EDGAR TRANSMISSION U. S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E., Mail Stop 3030 Washington, D.C. 20549 Attn: Mr. Brian Soares Re: PowerMedChairs Registration Statement on Form S-1 Filed May 23, 2013 F |
|
| June 25, 2013 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON JUNE 25, 2013 REGISTRATION NO. 333-188781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PowerMedChairs (Exact name of registrant as specified in its charter) Nevada 3842 46-2111820 (State or Other Jurisdiction (Primary Standard |
|
| May 23, 2013 |
EX-10.1 5 ex101svcagr.htm SERVICE AGREEMENT Exhibit 10.1 SERVICE AGREEMENT THIS SERVICE AGREEMENT (the "Agreement") is made and entered into this 1st day of May, 2013 ("Effective Date") by and between PowerMedChairs, a Nevada corporation ("PMC"), and A&A Medical Supply, LLC, an Ohio limited liability company ("A&A"). RECITALS A. A&A is engaged in the business of marketing, selling, and repairing m |
|
| May 23, 2013 |
S-1 1 pmcregstmt.htm AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON MAY 22, 2013 REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PowerMedChairs (Exact name of registrant as specified in its charter) Nevada 3842 46-2111820 (State or Other Jurisdiction (Primary Standard Indus |
|
| May 23, 2013 |
Articles of Incorporation (PURSUANT TO NRS CHAPTER 78) Exhibit 3.1 - Articles of Incorporation Document Number 20130120034-36 Filing Date and Time 02/22/2013 1:21PM Entity Number E0093122013-4 Filed in the office of /s/ Ross Miller Ross Miller Secretary of State ROSS MILLER Secretary of State /State Seal/ 101 North Carson Street, Suite 3 Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Articles of Incorporation (PURSUANT TO |
|
| May 23, 2013 |
EX-3.2 3 ex32bylaws.htm BYLAWS Exhibit 3.2 - By-laws BYLAWS OF PowerMedChairs As adopted on February 22, 2013 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice Of Stockholders’ Meetings 2 2.5 Manner Of Giving Notice; Affidavit Of Notice |
